Investigating how ALDH affects resistance to cancer treatment in ovarian cancer
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer
This study is looking at how a certain enzyme called ALDH helps ovarian cancer cells resist new treatments called PARP inhibitors, with the goal of finding ways to make these treatments more effective for patients with BRCA1 or BRCA2 mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11120950 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific enzyme, ALDH, contributes to the resistance of ovarian cancer cells to a new class of anticancer drugs known as PARP inhibitors. The study will explore the mechanisms by which ALDH enhances the cancer cells' ability to repair DNA damage, which is crucial for their survival despite treatment. By examining the relationship between ALDH activity and DNA repair pathways, the research aims to identify potential strategies to overcome treatment resistance in patients with BRCA1 or BRCA2 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with ovarian cancer who have BRCA1 or BRCA2 mutations and are undergoing treatment with PARP inhibitors.
Not a fit: Patients with ovarian cancer who do not have BRCA1 or BRCA2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for ovarian cancer patients who currently experience resistance to PARP inhibitors.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of drug resistance in cancer, making this approach both relevant and potentially impactful.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Wang, Qien — Ohio State University
- Study coordinator: Wang, Qien
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.